• Novo Nordisk presented two analyses of its REDEFINE 1 obesity trial at The Menopause Society 2026 Annual Meeting.
• Investigational CagriSema produced significant weight loss versus placebo in women across menopausal stages, with reductions in waist circumference.
• Gastrointestinal side effects were mostly transient and mild to moderate; treatment discontinuations were more common with CagriSema than placebo.
• The once-weekly treatment combines semaglutide with cagrilintide. A U.S. application was filed in December 2025, with a decision expected in Q4 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novo Nordisk A/S published the original content used to generate this news brief on October 20, 2026, and is solely responsible for the information contained therein.